Introduction
============

Vitamin K antagonists, especially warfarin, have traditionally been a cornerstone of anticoagulation therapy in the prevention and treatment of thromboembolic events. The main indication for warfarin therapy is atrial fibrillation (40%--65% of patients), followed by venous thrombosis, pulmonary embolism, and heart valve replacement.[@b1-clep-8-023]--[@b4-clep-8-023] Despite its well-established efficacy,[@b5-clep-8-023],[@b6-clep-8-023] warfarin therapy also involves a substantial risk of bleeding. In observational studies representing real-world clinical practice, the incidence of bleeding ranges from 1.9% to 7.6% per person-year (PY) among patients with atrial fibrillation receiving warfarin therapy.[@b4-clep-8-023],[@b7-clep-8-023]--[@b16-clep-8-023]

The incidence of bleeding has been shown to peak in the beginning of warfarin therapy,[@b11-clep-8-023],[@b17-clep-8-023] being the highest during the first month after warfarin initiation.[@b11-clep-8-023] The early peak may arise from early attrition of those most susceptible to bleeding.[@b18-clep-8-023] In addition, it may be related to difficulty to achieve the narrow therapeutic range (international normalized ratio \[INR\] 2--3). Specifically, warfarin dose--response is influenced by many factors, such as patient's age, diet, and various drugs and comorbidities that may alter warfarin metabolism.[@b19-clep-8-023] In addition, polymorphisms in *CYP2C9* and *VKORC1* genes have an important contribution to warfarin dose--response.[@b20-clep-8-023] While INR above therapeutic range (INR \>3) is a significant risk factor for bleeding,[@b21-clep-8-023] more than half of bleeding events occur within or below therapeutic range.[@b22-clep-8-023],[@b23-clep-8-023] Other factors, such as comorbidities and drugs, that increase bleeding risk without altering warfarin metabolism or activity of coagulation factors can contribute to these events; therefore, they cannot be avoided by INR monitoring and subsequent changes in warfarin dosing. Characterization of those most susceptible to early bleeding is important in order to increase the safety of warfarin initiation.

In this nationwide population-based cohort study, we examined the rate of serious bleeding, defined as bleeding requiring hospitalization, among noninstitutionalized Finnish persons initiating warfarin therapy over up to 4 years of follow-up. In addition, we characterized persons with an early bleeding requiring hospitalization in terms of comorbidities and exposure to interacting drugs.

Patients and methods
====================

Setting and data sources
------------------------

We conducted a nationwide population-based cohort study among noninstitutionalized Finnish persons initiating warfarin therapy between January 1, 2009, and June 30, 2012. We followed the initiators from the warfarin initiation date until December 31, 2012. We assembled the data by linking nationwide health registers maintained by the Social Insurance Institution (SII) and the National Institute for Health and Welfare (THL). The SII provided data on dispensed prescription drugs, demographics, dates of death, special reimbursements, and long-term institutional care (\>90 days of uninterrupted stays in public nursing homes or hospitals). The THL provided data on hospitalizations.

The Prescription Register includes information on reimbursed prescription drugs dispensed to community-dwelling residents of Finland.[@b24-clep-8-023] The information on drug use in public nursing homes and hospitals is supplied by the service provider and, therefore, not covered by the Prescription Register. For each reimbursed drug, the Prescription Register contains Anatomical Therapeutic Chemical classification code,[@b25-clep-8-023] dispensing date, strength, and quantity dispensed. No structured information on prescribed dose, duration of therapy, or indication is recorded. Furthermore, the Prescription Register contains data neither on nonreimbursed nor over-the-counter drugs (eg, low-dose acetylsalicylic acid). According to Finnish reimbursement rules, drugs can be reimbursed for a maximum of 3 months supply at one dispensing.[@b26-clep-8-023] The Special Reimbursement Register contains information on entitlements to special reimbursement (either 65% or 100% of drug costs in 2015) due to certain severe and chronic diseases. In order to be eligible for special reimbursement, a patient's disease must meet explicit criteria proved by a certificate from a physician. The Hospital Discharge Register contains information on hospital admissions, including inpatient care, day surgeries, and specialized outpatient care in public hospitals.[@b27-clep-8-023] Data on diagnoses and medical procedures are registered using the International Classification of Diseases (ICD) codes (ICD-10 since 1996) and the Nordic Medico-Statistical Committee classification of surgical procedures.

Warfarin initiators
-------------------

Using data from the Prescription Register, we identified persons initiating warfarin therapy between January 1, 2009 and June 30, 2012. We defined initiators as persons who filled a prescription for warfarin during the study period but had not been dispensed warfarin within the previous 365 days. We excluded persons who had been in long-term institutional care any time preceding warfarin initiation and persons with a hospital stay lasting continuously for \>90 days during the 365 days preceding warfarin initiation in order to confirm that our cohort of initiators did not include persons who may have used warfarin earlier during long-term institutional or hospital care.

Warfarin exposure
-----------------

Due to the lack of data on the duration of warfarin prescriptions, we present the rate of bleedings requiring hospitalization for the entire follow-up and separately for the first warfarin episode. To estimate the length of the first warfarin episode, we determined a fixed duration for each warfarin prescription using the waiting time distribution (WTD) method.[@b28-clep-8-023] Specifically, we identified prevalent warfarin users in 2012, defined as those who had been dispensed warfarin also in 2011, and determined the number of days (since January 1, 2012) in which 80% of these prevalent users were dispensed warfarin for the first time in 2012. Then, we assigned each warfarin prescription a fixed duration obtained this way (111 days). Warfarin episode was deemed to continue until the gap between consecutive dispensations exceeded 111 days. Our WTD estimate was similar for both dose sizes of warfarin (103 days for 3 mg and 115 days for 5 mg) and robust over time (110--113 days using data from 2009 to 2011). In Finland, warfarin is available in packages of 100 tablets only. To allow for doses less than one tablet per day, periodic dose adjustments, and interruptions in home medication for various reasons, we conducted a sensitivity analysis extending the fixed duration assigned for each prescription to 180 days.[@b11-clep-8-023] That is, the first warfarin episode was assumed to continue until the gap between consecutive dispensations exceeded 180 days.

Bleeding events
---------------

We determined a bleeding event as an admission to hospital for bleeding. We identified relevant admissions on the basis of primary discharge diagnoses using a list of ICD-10 codes adapted from Gomes et al[@b11-clep-8-023] ([Table S1](#SD2-clep-8-023){ref-type="supplementary-material"}). We categorized bleeding events further as intracranial, gastrointestinal, and others. We defined early bleeders as persons with a bleeding event within 30 days of warfarin initiation. The rest of the warfarin initiators were defined as nonearly bleeders, including those with bleeding event later than 30 days of warfarin initiation and those without bleeding event during the follow-up. We defined fatal bleeding events as those where the patient died within 10 days of the hospital admission.

Indications, comorbidities, and medications
-------------------------------------------

We determined indications, comorbidities, and medications at warfarin initiation date based on data on hospital admissions, special reimbursement codes, and/or dispensed drugs captured from the nationwide health registers ([Figure 1](#f1-clep-8-023){ref-type="fig"}). Detailed ICD codes, reimbursement codes, and Anatomical Therapeutic Chemical classification codes are available in [Table S1](#SD2-clep-8-023){ref-type="supplementary-material"}. To describe bleeding risk, we combined data on age, sex, and malignancy.[@b29-clep-8-023] To define stroke risk (congestive heart failure, hypertension, age ≥75, diabetes and stroke \[CHADS~2~\], reflects stroke risk in patients with atrial fibrillation not receiving anticoagulant therapy), we combined data on heart failure, hypertension, age ≥75 years, diabetes, and ischemic stroke/transient ischemic attack.[@b30-clep-8-023] We determined Charlson comorbidity index by identifying 17 comorbidities based on hospital admissions over a 1-year period preceding the warfarin initiation date.[@b31-clep-8-023]

Interacting drugs
-----------------

We determined exposure to interacting drugs at warfarin initiation date ([Figure 1](#f1-clep-8-023){ref-type="fig"}). A person was considered as exposed if interacting drug prescription overlapped with the warfarin initiation date or was filled at the warfarin initiation date. We identified drugs having potential for clinically significant interaction with warfarin from the Swedish, Finnish, Interaction X-referencing drug--drug interaction database.[@b32-clep-8-023] We defined the duration of each interacting drug prescription (except those for antimicrobials) based on the quantity dispensed, assuming a dosage equal to one defined daily dose per day.[@b25-clep-8-023] However, we truncated the duration to 100 days, that is, the maximum duration of treatment reimbursed at one dispensing.[@b26-clep-8-023] Finally, we multiplied the duration by 1.5 to allow for nonadherence. We defined the duration of each prescription for antimicrobials as 7 days.

Analyses
--------

We calculated the rate of bleeding events for the entire follow-up by dividing the number of persons with a bleeding event by the sum of PYs of follow-up. The follow-up started from the warfarin initiation and lasted until the first bleeding event, death, or administrative end of the study (December 31, 2012), whichever occurred first. The rate of bleeding events for the first 14-day period and for each 30-day period (months) starting from warfarin initiation was calculated among those alive at the beginning of the period and without bleeding event in the previous periods. In the site-specific analyses of bleeding rate (intracranial, gastrointestinal, and other), bleeding events in other sites did not cause censoring of follow-up. In addition, we calculated the rate of bleeding events during the first warfarin episode; the follow-up started from the warfarin initiation date and lasted until the end of the first warfarin episode, the first bleeding event, long-term institutional care, or \>90-day admission to hospital, death, or administrative end of the study, whichever occurred first.

We characterized early bleeders and nonearly bleeders by known and potential risk factors for bleeding measured by the register data at warfarin initiation, including age, sex, indication for warfarin therapy, bleeding history, comorbidities, medications, Charlson comorbidity index, bleeding risk score, CHADS~2~ score, and exposure to interacting drugs.

In addition, we performed age-adjusted and multivariable-adjusted Cox proportional hazards regression analyses to determine characteristics associated with an early bleeding event, expressing the results as hazard ratios (HRs) and their 95% confidence intervals (CIs). The potential predictors were age, sex, indications for warfarin therapy, history of any bleeding requiring hospitalization \<180 days before and during 180 days--7 years before warfarin initiation, individual comorbidities, Charlson comorbidity index, number of drugs in use during the year preceding warfarin initiation, and exposure to interacting drugs at warfarin initiation. The results of the multivariable analyses are presented with and without adjustment for the Charlson comorbidity index (as this index includes many of the separately measured disease states) and the number of drugs (as the number of drugs is also a measure of overall morbidity). The bleeding risk and CHADS~2~ scores are combinations of age and other variables already in the model; therefore, these scores were excluded from the age-adjusted and multivariable-adjusted analyses.

The proportional hazards assumption was checked both graphically and by testing the significance of the interaction term between the predictor and logarithmic time. The assumption was found to be reasonably fulfilled except for the variable history of any bleeding requiring hospitalization \<180 days before warfarin initiation. This variable was included in the multivariable Cox proportional hazards models as a stratifying variable. In addition, we performed multicollinearity diagnostics for all the predictors included in the multivariable Cox models; we did not observe any sign of strong multicollinearity as the values of the variance inflation factor were \<5 for all predictors.

Ethical issues
--------------

This study was institutionally approved by SII and THL. As the research team received only deidentified data and the patients were not contacted, consent was neither required by SII or THL, nor sought by the authors.

Results
=======

A total of 102,048 persons initiated warfarin therapy between January 1, 2009 and June 30, 2012. We excluded 460 persons as they had been in long-term institutional care before warfarin initiation or were continuously hospitalized for \>90 days during the preceding year. Finally, our study population consisted of 101,588 warfarin initiators.

Rate of bleeding events
-----------------------

Of warfarin initiators, 5,354 were hospitalized for a bleeding during the entire follow-up of 204,592 PYs (median 1.9 years, interquartile range \[IQR\]: 1.1--2.9 years), resulting in a rate of 2.6% per PY ([Table 1](#t1-clep-8-023){ref-type="table"}). The rate was the highest early after warfarin initiation, being 7.9% per PY (95% CI 7.05%--8.8%) for the first 14 days and 6.5% per PY (95% CI 6.0%--7.1%) for the first 30 days. After the first 12 months, the rate stabilized \~2% per PY ([Figure 2](#f2-clep-8-023){ref-type="fig"}). Among warfarin initiators, 81.7% (n=83,046) discontinued therapy during the follow-up and half of them (n=43,750) after the first warfarin prescription. The median duration of the first warfarin episode was 5.5 months (IQR: 3.7--9.5 months). The number of initiators with a bleeding event during the first warfarin episode (altogether 69,656 PYs) was 2,283, resulting in a rate of 3.3% per PY (95% CI 3.1--3.4). When the first warfarin episode was assumed to continue until the gap between consecutive prescriptions exceeded 180 days (instead of 111 days), the median duration of the episode was 10.6 months (IQR: 6--20.1 months) and the rate of any bleeding requiring hospitalization was 3.0% per PY (95% CI 2.9--3.1). [Figure S1](#SD1-clep-8-023){ref-type="supplementary-material"} shows the rate of bleeding events during the first warfarin episode on the assumptions of prescription duration of 111 and 180 days.

The rate of bleeding events during the entire follow-up was similar across indications (from 2.9% to 3.1% per PY), with the exception of lower rate among those with venous thrombosis (2.1% per PY, 95% CI 2.0--2.3). The rate of bleeding events within the first 30 days of warfarin initiation was the highest among those with pulmonary embolism (10.9% per PY 95% CI 8.4%--13.9%) or venous thrombosis (10.2% per PY, 95% CI 8.3%--12.5%).

The distribution of bleeding site was similar among all 5,354 bleeding events and among 539 early bleeding events, with 16% of bleeding events being intracranial, \~35% gastrointestinal, and \~49% other bleedings. Overall, 5.3% (n=283) of all bleeding events (200 of intracranial, 68 of gastrointestinal, and 15 of other bleeding events) and 2.6% (n=14) of early bleeding events were fatal (eight of intracranial, five of gastrointestinal, and one of other bleedings).

Characteristics of early bleeders
---------------------------------

Among 539 early bleeders, 74.0% were ≥65 years and 56.4% were men. Nonearly bleeders were younger and less frequently men than early bleeders ([Table 2](#t2-clep-8-023){ref-type="table"}). Approximately 40% of both early bleeders and nonearly bleeders had atrial fibrillation. One-third of early bleeders (31.0%) and less than one-tenth of nonearly bleeders (7.4%) had a history of bleeding. Most of the addressed comorbidities and medications were more common among early bleeders than among nonearly bleeders. In addition, early bleeders were more frequently exposed to interacting drugs (67.5%) than nonearly bleeders (57.1%) ([Table 3](#t3-clep-8-023){ref-type="table"}). The hazard of early bleeding did not increase consistently with an increasing value of the bleeding risk score ([Table 2](#t2-clep-8-023){ref-type="table"}). Among those identified as patients with atrial fibrillation, a CHADS~2~ score \>2 predicted an 87% increase in the hazard of early bleeding.

Based on multivariable Cox proportional hazards regression analysis, those with a history of bleeding were most likely to experience an early bleeding ([Table 4](#t4-clep-8-023){ref-type="table"}). The HR for early bleeding associated with the history of bleeding during 180 days--7 years before warfarin initiation variable was 1.48 (95% CI 1.15--1.91). When history of bleeding within \<180 days prior to initiation was not treated as a stratifying variable, its (average) HR was 13.7 (95% CI 10.9--17.1). In addition, early bleeders were characterized by older age (HR =1.13, 95% CI 1.04--1.22, per 10-year increase in age), male sex (HR =1.32, 95% CI 1.10--1.57), venous thrombosis (HR =1.83, 95% CI 1.44--2.34), pulmonary embolism (HR =1.46, 95% CI 1.11--1.91), alcohol abuse (HR =1.59, 95% CI 1.08--2.35), rheumatic disease (HR =1.40, 95% CI 1.07--1.83), and exposure to drugs with dynamic mechanism of interaction with warfarin (HR =1.43, 95% CI 1.20--1.71). When the model was further adjusted for Charlson comorbidity index and the number of drugs in use during the past year, the preceding associations were slightly attenuated and the HR for rheumatic disease was not significant any more. In age-adjusted models, Charlson comorbidity index and number of drugs predicted a steep graded increase in the hazard of early bleeding; these associations were attenuated when adjusted for other predictors.

Discussion
==========

In this population-based cohort study, we found that the rate of bleeding leading to hospitalization was 2.6% per PY among noninstitutionalized Finnish persons initiating warfarin therapy over a median of 1.9 years of follow-up. The rate of bleeding requiring hospitalization peaked within the first month of warfarin initiation (6.5% per PY), especially among those with pulmonary embolism or venous thrombosis. One-third of early bleeders had a history of bleeding. Besides being characterized by prior bleeding, pulmonary embolism, or venous thrombosis, early bleeders were older, male, had history of alcohol abuse or rheumatic disease, and were using drugs with pharmacodynamic interaction mechanism with warfarin.

The rate of bleeding hospitalizations was higher during the first warfarin episode (3.0%--3.3% per PY) than during the entire follow-up (2.6% per PY). This may result from the fact that \~40% of the initiators discontinued therapy after the first prescription, and therefore, the first warfarin episode emphasized the beginning of therapy when the rate of bleeding was the highest. In addition, the difference may arise from the fact that the entire follow-up included person-time after warfarin discontinuation. However, the incidence of bleeding may not decrease immediately after the end of warfarin therapy since factors leading to discontinuation may be related to the appearance of early signs of bleeding. One previous study showed a minor increase in the bleeding incidence during the first month after warfarin discontinuation, but a decrease thereafter.[@b10-clep-8-023]

Our estimates on the rate of bleeding among warfarin initiators fall within the range of 1.9%--7.6% per PY, which was reported previously by observational studies among patients with atrial fibrillation receiving warfarin therapy.[@b4-clep-8-023],[@b7-clep-8-023]--[@b16-clep-8-023] Differences in the rates between the studies may largely emerge due to differences in the definitions of bleeding, the age distribution of the study populations, and the length of follow-up (as the incidence peaks in the beginning of warfarin therapy). Moreover, many studies have not excluded persons with prior warfarin exposure, resulting in the underestimation of early events. In our study, the rate of bleeding among those with verified atrial fibrillation was 2.9% per PY during the first warfarin episode (data not shown), being somewhat smaller than that (3.8% per PY) reported in a Canadian study with a similar definition for bleeding events among patients with atrial fibrillation during their first warfarin episode.[@b11-clep-8-023] We used a stricter definition for a bleeding event (identified based on primary discharge diagnoses only) and our study population was younger, which may explain the difference in the rates.

The peak in the bleeding rate in the beginning of warfarin therapy may arise from difficulty to achieve the target INR.[@b18-clep-8-023] However, in the absence of data on INR values, we were unable to assess whether early bleedings occurred at INR above the therapeutic range. In Finland, persons on warfarin therapy have been reported to spend on an average \~13% of the time above the therapeutic range,[@b33-clep-8-023],[@b34-clep-8-023] but there are no data whether this proportion is higher in the beginning of therapy. In a British study, time spent above the therapeutic range was 20% in the first month after warfarin initiation and \~15% in the following 2 years,[@b35-clep-8-023] suggesting that the time spent above the therapeutic range varies modestly across the duration of therapy.

The early peak in the rate of bleeding may further result from the early attrition of those most susceptible to bleeding.[@b18-clep-8-023] We found that early bleeders were characterized by prior bleeding, older age, history of alcohol abuse, and exposure to drugs with pharmacodynamic interaction mechanism with warfarin, all of which increase the bleeding risk without affecting the INR. Therefore, the initiation of warfarin therapy in the presence of these characteristics requires particular consideration and monitoring, as well as careful evaluation of prior medication. Unfortunately, we could not evaluate the exposure to low-dose acetylsalicylic acid, the use of which is common among warfarin initiators[@b13-clep-8-023] and has been associated with an increased bleeding risk during warfarin therapy.[@b12-clep-8-023],[@b36-clep-8-023],[@b37-clep-8-023] In addition, it should be noted that early bleeders may have suffered from undiagnosed and untreated comorbidities, such as peptic ulcer or malignancy, that have predisposed them to bleeding.

The peak in the rate of bleeding during the first month after warfarin initiation was most prominent among persons with pulmonary embolism (10.9% per PY) or venous thrombosis (10.2% per PY). We do not have an explicit explanation for our observation, but it could be related to the fact that those with pulmonary embolism or venous thrombosis were more frequently exposed to nonsteroidal anti-inflammatory drugs (NSAIDs) at warfarin initiation (13.1% and 18.3%, respectively) than those receiving warfarin for other indications (7.2%--8.9%); however, when we added NSAID use at warfarin initiation to our multivariable model, the HRs for venous thrombosis or pulmonary embolism did not change (data not shown). In addition, those with pulmonary embolism or venous thrombosis may have been exposed to higher warfarin doses, an important risk factor for bleeding.[@b38-clep-8-023] Nonetheless, those with venous thrombosis and pulmonary embolism had higher rates of bleeding events only in the beginning of warfarin therapy, not during the entire follow-up. This accords with previous studies not illustrating a higher incidence of bleeding among those with venous thrombosis compared with other indications.[@b4-clep-8-023],[@b39-clep-8-023]

Early bleedings were further predicted by rheumatic disease. Persons with rheumatic disease were commonly exposed to corticosteroids (29.2%) and NSAIDs (17.8%) at warfarin initiation; however, the inclusion of the use of NSAIDs in the multivariable model did not affect the HR for early bleeding associated with rheumatic disease.

In our study, the proportion of fatal bleedings was lower (5.3%) than those observed in previous studies (7.2%--18.1%).[@b10-clep-8-023],[@b11-clep-8-023] This was evident for the proportion of fatal intracranial bleedings as well (21.6% vs \~40%),[@b10-clep-8-023],[@b11-clep-8-023] suggesting that the lower proportion was not due to inclusion of less severe bleedings. The lower proportion was also not due to younger study population since the proportion of fatal bleedings increased only modestly (6.1%) when those aged \<65 years were excluded. Furthermore, the lower proportion is not likely to be explained by our approach to include all indications since indication for warfarin therapy appears to have a limited impact on fatality of bleeding.[@b39-clep-8-023]

Methodological considerations
-----------------------------

The strengths of our study include a large study sample representative to noninstitutionalized Finnish population, up-to-date data, and comprehensive data sources. In addition, by following initiators, instead of prevalent warfarin users, we were able to detect the early peak in the rate of bleeding. In addition, our data are from the time before non-vitamin K antagonist oral anticoagulants became reimbursable among patients with atrial fibrillation, pulmonary embolism, or venous thrombosis,[@b40-clep-8-023] and therefore, our cohort represents the whole range of oral anticoagulant initiators.

Some limitations need to be noted. First, we did not have data on minor bleedings that did not result in hospital admission or fatal bleedings leading to death without hospital admission, resulting in underestimation of the rate of bleeding events. Second, there are no validation studies dealing with the quality of the Hospital Discharge Register for bleeding events except for intracranial hemorrhage. Overall, the completeness and accuracy of this register have been shown to be at least satisfactory and good in case of intracranial hemorrhage.[@b24-clep-8-023] The present study identified bleeding-related hospital admissions with primary ICD-10 codes, which decreases the likelihood of misclassification of patient's prior bleeding as an event. Clinically, it is reasonable to assume that major bleedings are coded accurately. In fact, one Canadian validation study showed that the ICD codes have good sensitivity (93%), specificity (88%), and positive predictive (91%), and negative predictive values (91%) for the identification of warfarin-related bleedings when compared to medical records.[@b41-clep-8-023] Third, our data of indications and comorbidities are not complete since they were based on administrative health registers, and we did not have access to primary care registers.[@b42-clep-8-023] Such misclassification may have diluted the observed associations between comorbidities and the hazard of early bleeding. Fourth, as in any study based on pharmacy dispensation data, we have no way of knowing whether and when the dispensed warfarin was actually consumed. In the absence of data on INR monitoring, we could not assess whether early bleeding events were related to supratherapeutic INR values. As we had no information on the duration of each warfarin prescription, we used a data-driven WTD as a proxy and conducted sensitivity analyses extending the prescription duration to 180 days. The main and sensitivity analyses produced similar results. In addition, we do not know whether the exposure to interacting drugs continued after warfarin initiation. Nevertheless, we previously showed that the interacting drugs are frequently prescribed within the first month of warfarin initiation,[@b43-clep-8-023] suggesting that warfarin initiation seldom results in the discontinuation of interacting drugs, with the exception of NSAIDs.[@b40-clep-8-023] Moreover, we may have underestimated exposure to ibuprofen, ketoprofen, and paracetamol as small packages are available over the counter. Finally, exposure to low-dose acetylsalicylic acid (over-the-counter product), alternative medications, dietary factors, smoking, and alcohol was out of reach in our study.

Conclusion
==========

Our population-based cohort study indicated that the rate of bleeding was the highest in the beginning of warfarin therapy. Persons most susceptible to an early bleeding were characterized by venous thrombosis and pulmonary embolism and factors that increase bleeding risk without alteration in the INR. Therefore, the initiation of warfarin therapy in the presence of these factors requires careful consideration and monitoring.

Supplementary material
======================

###### 

Rate of bleedings requiring hospitalization for each month of the first warfarin episode when the episode was assumed to continue until the gap between consecutive dispensations exceeded 111 days (**A**) or 180 days (**B**).

###### 

Identification of bleeding events, indications, comorbidities, and medications

  Bleeding events, indications, comorbidities and medications   ICD-10 codes/procedure codes                                                                                                                                                                                                                                                                                                                                                              Reimbursement codes       ATC codes
  ------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------- -----------------------------------------------------------------------------------------------------------------
  Bleedings[a](#tfn12-clep-8-023){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                                                                                                                              
   Intracranial                                                 I60[\*](#tfn13-clep-8-023){ref-type="table-fn"}, I61[\*](#tfn13-clep-8-023){ref-type="table-fn"}, I62[\*](#tfn13-clep-8-023){ref-type="table-fn"}                                                                                                                                                                                                                                                                   
   Gastrointestinal                                             K920, K921, K922, I850, K221, K250, K252, K254, K256, K260, K262, K264, K266, K270, K272, K274, K276, K280, K282, K284, K286, K290, K625                                                                                                                                                                                                                                                                            
   Other                                                        N02[\*](#tfn13-clep-8-023){ref-type="table-fn"}, K661, N938, N939, N950, R041, R042, R048, R049, R31, R58, D683, H356, H431, H450, M250                                                                                                                                                                                                                                                                             
  Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
   Atrial fibrillation                                          I48[\*](#tfn13-clep-8-023){ref-type="table-fn"}, FPD[\*](#tfn13-clep-8-023){ref-type="table-fn"}, TFP46, TFP20                                                                                                                                                                                                                                                                            207 (based on I48)        
   Venous thrombosis                                            I80[\*](#tfn13-clep-8-023){ref-type="table-fn"}, I81[\*](#tfn13-clep-8-023){ref-type="table-fn"}, I82[\*](#tfn13-clep-8-023){ref-type="table-fn"} (not I801)                                                                                                                                                                                                                                                        
   Mechanical heart valve                                       Z952[\*](#tfn13-clep-8-023){ref-type="table-fn"}, FJ[\*](#tfn13-clep-8-023){ref-type="table-fn"}, FK[\*](#tfn13-clep-8-023){ref-type="table-fn"}, FM[\*](#tfn13-clep-8-023){ref-type="table-fn"}, FG[\*](#tfn13-clep-8-023){ref-type="table-fn"}                                                                                                                                                                    
   Pulmonary embolism                                           I26[\*](#tfn13-clep-8-023){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                                                                     
   Ischemic stroke/TIA                                          I63[\*](#tfn13-clep-8-023){ref-type="table-fn"}, G45[\*](#tfn13-clep-8-023){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                    
  Comorbidities                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
   Coronary artery disease                                      I20[\*](#tfn13-clep-8-023){ref-type="table-fn"}--I25[\*](#tfn13-clep-8-023){ref-type="table-fn"}/FNA[\*](#tfn13-clep-8-023){ref-type="table-fn"}, FNB[\*](#tfn13-clep-8-023){ref-type="table-fn"}, FNC[\*](#tfn13-clep-8-023){ref-type="table-fn"}, FND[\*](#tfn13-clep-8-023){ref-type="table-fn"}, FNE[\*](#tfn13-clep-8-023){ref-type="table-fn"}, FN1AT, FN1BT, FN1YT, TFN40, TFN50   206                       C01
   Heart failure                                                I50[\*](#tfn13-clep-8-023){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                                           201                       
   Ischemic stroke/TIA                                          I63[\*](#tfn13-clep-8-023){ref-type="table-fn"}--I66[\*](#tfn13-clep-8-023){ref-type="table-fn"}, G45[\*](#tfn13-clep-8-023){ref-type="table-fn"}                                                                                                                                                                                                                                                                   
   Hypertension                                                 I10[\*](#tfn13-clep-8-023){ref-type="table-fn"}--I15[\*](#tfn13-clep-8-023){ref-type="table-fn"}                                                                                                                                                                                                                                                                                          205                       
   Peripheral arterial disease                                  I70[\*](#tfn13-clep-8-023){ref-type="table-fn"}, I74[\*](#tfn13-clep-8-023){ref-type="table-fn"}/PFH[\*](#tfn13-clep-8-023){ref-type="table-fn"}, PDQ[\*](#tfn13-clep-8-023){ref-type="table-fn"}, PEQ[\*](#tfn13-clep-8-023){ref-type="table-fn"}, PFQ[\*](#tfn13-clep-8-023){ref-type="table-fn"}, PF1AT, PF1BT, PE1AT, PE1BT                                                           211                       
   Thrombosis in cerebral arteries or in intracranial veins     I65[\*](#tfn13-clep-8-023){ref-type="table-fn"}, I66[\*](#tfn13-clep-8-023){ref-type="table-fn"}, I676                                                                                                                                                                                                                                                                                                              
   Diabetes                                                     E10[\*](#tfn13-clep-8-023){ref-type="table-fn"}--E14[\*](#tfn13-clep-8-023){ref-type="table-fn"}                                                                                                                                                                                                                                                                                          103                       A10
   Renal impairment                                             N04[\*](#tfn13-clep-8-023){ref-type="table-fn"}, N17[\*](#tfn13-clep-8-023){ref-type="table-fn"}--N19[\*](#tfn13-clep-8-023){ref-type="table-fn"}, N258, Z491, Z492                                                                                                                                                                                                                       123, 137, 138, 190, 320   
   Liver disease                                                K70[\*](#tfn13-clep-8-023){ref-type="table-fn"}--K77[\*](#tfn13-clep-8-023){ref-type="table-fn"}, B15[\*](#tfn13-clep-8-023){ref-type="table-fn"}--B19[\*](#tfn13-clep-8-023){ref-type="table-fn"}, B942                                                                                                                                                                                                            
   Dementia                                                     F00[\*](#tfn13-clep-8-023){ref-type="table-fn"}, F01[\*](#tfn13-clep-8-023){ref-type="table-fn"}, F03[\*](#tfn13-clep-8-023){ref-type="table-fn"}, G30[\*](#tfn13-clep-8-023){ref-type="table-fn"}                                                                                                                                                                                        307                       N06D
   Malignancy                                                   C00[\*](#tfn13-clep-8-023){ref-type="table-fn"}--C99[\*](#tfn13-clep-8-023){ref-type="table-fn"}, D00[\*](#tfn13-clep-8-023){ref-type="table-fn"}--D09[\*](#tfn13-clep-8-023){ref-type="table-fn"}                                                                                                                                                                                        115--117, 128, 130        L01[\*](#tfn13-clep-8-023){ref-type="table-fn"}, L02B[\*](#tfn13-clep-8-023){ref-type="table-fn"} (not L01BA01)
   Alcohol abuse                                                E244, F10[\*](#tfn13-clep-8-023){ref-type="table-fn"}, G312, G4051, G621, G721, I426, K292, K70[\*](#tfn13-clep-8-023){ref-type="table-fn"}, K852, K860, R780, T510, Y911, Y912, Y913, Y919, Z502, Z714                                                                                                                                                                                                             N07BB
   Pulmonary disease                                            J44[\*](#tfn13-clep-8-023){ref-type="table-fn"}--J46[\*](#tfn13-clep-8-023){ref-type="table-fn"}                                                                                                                                                                                                                                                                                          203                       R03
   Rheumatic disease                                            M05[\*](#tfn13-clep-8-023){ref-type="table-fn"}--M09[\*](#tfn13-clep-8-023){ref-type="table-fn"}, M13[\*](#tfn13-clep-8-023){ref-type="table-fn"}, M31[\*](#tfn13-clep-8-023){ref-type="table-fn"}--M36[\*](#tfn13-clep-8-023){ref-type="table-fn"}, M45[\*](#tfn13-clep-8-023){ref-type="table-fn"}, M46[\*](#tfn13-clep-8-023){ref-type="table-fn"}                                     202, 281, 313             
   Gastrointestinal disease                                     K21[\*](#tfn13-clep-8-023){ref-type="table-fn"}, K223, K251, K253, K255, K257, K259, K261, K263, K265, K267, K269, K271, K273, K275, K277, K279, K281, K283, K285, K287, K289, K633                                                                                                                                                                                                                                 A02B
  Medications                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
   Number of drugs                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Number of different ATC-codes
   Any cardiovascular drug                                                                                                                                                                                                                                                                                                                                                                                                                                                          C01--C04, C07--C09
   Antithrombotic drugs                                                                                                                                                                                                                                                                                                                                                                                                                                                             B01 (not B01AA03)
   Lipid-modifying drugs                                                                                                                                                                                                                                                                                                                                                                                                                                                            C10

**Notes:**

Data adapted from Gomes T, Mamdani MM, Holbrook AM, et al. Rates of hemorrhage during warfarin therapy for atrial fibrillation. *CMAJ*. 2013;185(2):E121--E127.[@b44-clep-8-023] Codes I9820, I983, K6380, and K3180 were excluded as they do not appear in the Finnish ICD-10 codes.

Includes all the diagnoses from the given ICD-10 code.

**Abbreviations:** ATC, Anatomical Therapeutic Chemical; ICD, International Classification of Diseases; TIA, transient ischemic attack.

The work was supported by a grant from the SII of Finland (11/26/2012). Milka Hauta-aho compiled the list of potentially interacting drugs. Arja Helin-Salmivaara served as a scientific advisor for variable definitions.
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![Measurement of indications, comorbidities, medications, and exposure to interacting drugs.\
**Notes:** ^a^A hospital admission within a 1-year period before or at the warfarin initiation date, or a valid entitlement to special reimbursement at the warfarin initiation date, or within a 3-month period after the warfarin initiation date. ^b^A hospital admission within a 7-year period before or at the warfarin initiation date, or a valid entitlement to special reimbursement at the warfarin initiation date, or a prescription dispensed within a 1-year period before or at the warfarin initiation date. ^c^A prescription dispensed within a 1-year period before or at the warfarin initiation date. ^d^A prescription overlapped with the warfarin initiation date, or a prescription dispensed at the warfarin initiation date.](clep-8-023Fig1){#f1-clep-8-023}

![Rate of bleedings requiring hospitalization during the entire follow-up for each month starting from warfarin initiation (n=101,588).\
**Abbreviation:** PY, person-year.](clep-8-023Fig2){#f2-clep-8-023}

###### 

Rate of bleedings requiring hospitalization (% per PY) among warfarin initiators during the first 30 days after initiation and during the entire follow-up (n=101,588)

  Bleeding site               First 30 days   Entire follow-up           
  --------------------------- --------------- ------------------ ------- ----------------
  Any bleeding                539             6.5 (6.0--7.1)     5,354   2.6 (2.5--2.7)
  Intracranial bleeding       83              1.0 (0.8--1.2)     920     0.4 (0.4--0.5)
  Gastrointestinal bleeding   192             2.3 (2.0--2.7)     1,874   0.9 (0.9--0.9)
  Other bleeding              267             3.2 (2.8--3.6)     2,721   1.3 (1.3--1.4)

**Abbreviations:** CI, confidence interval; PY, person-year.

###### 

Characteristics of early bleeders (n=539) and nonearly bleeders (n=101,049) at the warfarin initiation date

  Characteristics                                                      Early bleeders   Nonearly bleeders   Unadjusted HR (95 % CI)
  -------------------------------------------------------------------- ---------------- ------------------- -------------------------------------------------------------
  Demographics                                                                                              
   Men                                                                 56.4 (304)       51.5 (52,018)       1.22 (1.03--1.45)
   Age, years, median (IQR)                                            73 (64--81)      72 (62--80)         1.10 (1.03--1.17)[a](#tfn3-clep-8-023){ref-type="table-fn"}
    ≤64                                                                26.0 (140)       30.8 (31,081)       1.00 (reference)
    65--74                                                             27.5 (148)       26.5 (26,799)       1.23 (0.97--1.54)
    ≥75                                                                46.6 (251)       42.7 (43,169)       1.29 (1.05--1.59)
  Indications                                                                                               
   Atrial fibrillation                                                 37.9 (204)       40.1 (40,560)       0.91 (0.76--1.08)
   Venous thrombosis                                                   17.6 (95)        11.2 (11,272)       1.70 (1.36--2.12)
   Mechanical heart valve                                              12.1 (65)        12.0 (12,144)       1.00 (0.78--1.30)
   Pulmonary embolism                                                  12.2 (66)        7.3 (7,357)         1.78 (1.37--2.30)
   Ischemic stroke or transient ischemic attack                        11.5 (62)        8.9 (8,985)         1.33 (1.02--1.73)
  History of bleeding                                                                                       
   Any bleeding                                                        31.0 (167)       7.4 (7,523)         5.53 (4.61--6.64)
   1 day--\<180 days before warfarin initiation                        20.0 (108)       1.3 (1,345)         17.9 (14.5--22.2)
   180 days--7 years before warfarin initiation                        14.3 (77)        6.4 (6,490)         2.42 (1.90--3.08)
   Intracranial bleeding                                               6.7 (36)         0.7 (663)           10.6 (7.57--14.9)
   Gastrointestinal bleeding                                           8.9 (48)         2.9 (2,933)         3.25 (2.42--4.38)
   Other bleeding                                                      17.1 (92)        4.2 (4,207)         4.70 (3.75--5.88)
  Comorbidities                                                                                             
   Coronary artery disease                                             45.8 (247)       43.0 (43,445)       1.12 (0.95--1.33)
   Heart failure                                                       19.3 (104)       17.0 (17,179)       1.17 (0.95--1.45)
   Ischemic stroke or transient ischemic attack                        17.3 (93)        14.1 (14,260)       1.27 (1.01--1.59)
   Hypertension                                                        51.6 (278)       46.3 (46,782)       1.24 (1.04--1.46)
   Peripheral arterial disease                                         6.3 (34)         4.6 (4,657)         1.40 (0.99--1.98)
   Thrombosis in cerebral arteries or in intracranial veins            1.1 (6)          1.2 (1,190)         0.95 (0.42--2.11)
   Diabetes                                                            18.6 (100)       18.2 (18,431)       1.02 (0.82--1.27)
   Renal impairment                                                    4.6 (25)         2.5 (2,497)         1.92 (1.29--2.87)
   Liver disease                                                       2.2 (12)         1.0 (1,047)         2.17 (1.23--3.85)
   Dementia                                                            4.8 (26)         4.6 (4,691)         1.05 (0.71--1.55)
   Malignancy                                                          17.4 (94)        13.6 (13,742)       1.34 (1.08--1.68)
   Alcohol abuse                                                       5.8 (31)         3.0 (3,009)         1.98 (1.38--2.85)
   Pulmonary disease                                                   18.9 (102)       16.0 (16,121)       1.23 (0.99--1.53)
   Rheumatic disease                                                   11.7 (63)        7.1 (7,122)         1.74 (1.34--2.27)
   Gastrointestinal disease                                            42.3 (228)       31.3 (31,612)       1.61 (1.36--1.91)
   Charlson comorbidity index, median (IQR)                            1 (0--2)         0 (0--1)            1.27 (1.19--1.36)
  Medications                                                                                               
   Number of drugs, median (IQR)                                       10 (7--14)       9 (6--12)           1.82 (1.55--2.13)[b](#tfn4-clep-8-023){ref-type="table-fn"}
   Any cardiovascular drug                                             86.3 (465)       85.0 (85,908)       1.11 (0.87--1.42)
   Antithrombotic drugs                                                40.5 (218)       26.9 (27,180)       1.84 (1.55--2.19)
   Lipid-modifying drugs                                               44.5 (240)       43.2 (43,697)       1.05 (0.89--1.25)
  Bleeding risk score[c](#tfn5-clep-8-023){ref-type="table-fn"}                                             
   0                                                                   11.3 (61)        13.4 (13,497)       1.00 (reference)
   1.3--1.6                                                            40.3 (217)       38.5 (38,865)       1.24 (0.93--1.64)
   2.2--2.9                                                            32.1 (173)       35.1 (35,503)       1.08 (0.81--1.45)
   ≥3.5                                                                16.3 (88)        13.0 (13,184)       1.48 (1.07--2.05)
  CHADS~2~ score^d^ (among those with atrial fibrillation, n=40,764)                                        
   0                                                                   11.8 (24)        18.9 (7,662)        1.00 (reference)
   1                                                                   26.0 (53)        27.6 (11,191)       1.51 (0.93--2.45)
   2                                                                   30.4 (62)        26.1 (10,577)       1.87 (1.17--3.00)
   ≥3                                                                  31.9 (65)        27.4 (11,130)       1.87 (1.17--2.98)

**Notes:** Data shown as percentage (n), median (IQR), or unadjusted HR (95 % CI). HRs reported for presence versus absence of a characteristic unless otherwise stated.

Per 10 years.

Per one unit increase in the number of drugs measured on a logarithmic scale.

Bleeding risk score defined based on age, sex, and malignancy, and ranges from 0 to 5.1.^32\ d^CHADS~2~ score reflects the risk of stroke in persons with atrial fibrillation, defined based on heart failure, hypertension, age ≥75 years, diabetes, stroke/transient ischemic attack, and ranges from 0 to 6.[@b33-clep-8-023]

**Abbreviations:** CHADS~2~, congestive heart failure, hypertension, age ≥75, diabetes and stroke; CI, confidence interval; HR, hazard ratio; IQR, interquartile range.

###### 

Exposure to interacting drugs at the warfarin initiation date among early bleeders (n=539) and nonearly bleeders (n=101,049)

  Interacting drugs                                Early bleeders, % (n)   Nonearly bleeders, % (n)
  ------------------------------------------------ ----------------------- --------------------------
  Any interacting drug                             67.5 (364)              57.1 (57,731)
   One interacting drug                            37.9 (204)              35.5 (35,902)
   Two interacting drugs                           21.0 (113)              15.8 (15,958)
   Three or more interacting drugs                 8.7 (47)                5.8 (5,871)
  Any drug with dynamic mechanism of interaction   53.3 (287)              41.1 (41,493)
   Paracetamol                                     26.2 (141)              19.4 (19,574)
   Prednisolone                                    9.1 (49)                5.9 (5,907)
   Levothyroxine                                   7.6 (41)                6.8 (6,863)
   Clopidogrel                                     5.8 (31)                3.2 (3,278)
   Ibuprofen                                       5.6 (30)                5.3 (5,310)
   Citalopram                                      3.5 (19)                2.5 (2,546)
   Etoricoxib                                      3.0 (16)                1.5 (1,497)
   Escitalopram                                    2.6 (14)                1.6 (1,627)
   Tramadol                                        2.4 (13)                2.1 (2,166)
   Diclofenac                                      1.3 (7)                 1.3 (1,348)
   Naproxen                                        0.7 (4)                 1.0 (1,023)
   Dexamethasone                                   1.3 (7)                 0.4 (356)
   Methylprednisolone                              1.5 (8)                 0.5 (503)
   Meloxicam                                       0.9 (5)                 0.8 (837)
   Venlafaxine                                     0.6 (3)                 0.6 (610)
  Any drug with kinetic mechanism of interaction   3.3 (18)                3.3 (3,299)
   Amiodarone                                      0.9 (5)                 1.0 (1,014)
   Fluvastatin                                     0.7 (4)                 1.4 (1,377)
  Any drug with unclear mechanism of interaction   27.1 (146)              24.8 (25,055)
   Simvastatin                                     24.5 (132)              22.9 (23,180)
   Rosuvastatin                                    2.2 (12)                2.0 (2,003)
   Ciprofloxacin                                   0.9 (5)                 0.6 (586)
   Levofloxacin                                    1.3 (7)                 0.6 (607)
   Doxycycline                                     0.6 (3)                 0.7 (652)

**Notes:** Persons were considered as exposed if interacting drug prescription overlapped with the warfarin initiation date. Individual drugs with a prevalence of \<0.5% in both early and nonearly bleeders are excluded.

###### 

Factors associated with early bleeding among warfarin initiators (n=101,588)

  Factors                                                     Age-adjusted HR (95% CI)   Multivariable-adjusted HR (95% CI)[a](#tfn9-clep-8-023){ref-type="table-fn"}   Multivariable-adjusted HR (95% CI)[b](#tfn10-clep-8-023){ref-type="table-fn"}
  ----------------------------------------------------------- -------------------------- ------------------------------------------------------------------------------ -------------------------------------------------------------------------------
  Sex                                                                                                                                                                   
   Men                                                        1.30 (1.09--1.55)          1.32 (1.10--1.57)                                                              1.34 (1.11--1.60)
  Age                                                                                                                                                                   
   Per 10 years                                               NA                         1.13 (1.04--1.22)                                                              1.12 (1.04--1.21)
  Indications                                                                                                                                                           
   Atrial fibrillation                                        0.87 (0.73--1.03)          1.00 (0.83--1.21)                                                              0.98 (0.81--1.19)
   Venous thrombosis                                          1.94 (1.54--2.44)          1.83 (1.44--2.34)                                                              1.80 (1.41--2.92)
   Mechanical heart valve                                     1.04 (0.80--1.34)          0.99 (0.76--1.30)                                                              0.95 (0.73--1.24)
   Pulmonary embolism                                         1.85 (1.43--2.40)          1.46 (1.11--1.91)                                                              1.42 (1.09--1.87)
   Ischemic stroke or transient ischemic attack               1.31 (1.01--1.71)          1.22 (0.93--1.61)                                                              1.04 (0.77--1.39)
  History of bleeding                                                                                                                                                   
   During 1 day--\<180 days before warfarin initiation        17.7 (14.3--21.9)          NA                                                                             NA
   During 180 days--7 years before warfarin initiation        2.35 (1.84--2.99)          1.48 (1.15--1.90)                                                              1.46 (1.14--1.88)
  Comorbidities                                                                                                                                                         
   Coronary artery disease                                    1.04 (0.87--1.24)          1.00 (0.82--1.21)                                                              0.95 (0.78--1.15)
   Heart failure                                              1.10 (0.88--1.37)          1.04 (0.83--1.31)                                                              0.93 (0.73--1.18)
   Hypertension                                               1.17 (0.98--1.39)          1.13 (0.94--1.35)                                                              1.07 (0.89--1.29)
   Peripheral arterial disease                                1.34 (0.94--1.90)          1.11 (0.78--1.59)                                                              1.04 (0.73--1.49)
   Thrombosis in cerebral arteries or in intracranial veins   0.97 (0.43--2.16)          0.75 (0.33--1.68)                                                              0.72 (0.32--1.62)
   Diabetes                                                   0.99 (0.80--1.24)          0.88 (0.70--1.10)                                                              0.79 (0.63--1.01)
   Renal impairment                                           1.87 (1.25--2.79)          1.22 (0.81--1.85)                                                              1.09 (0.71--1.67)
   Liver disease                                              2.27 (1.28--4.02)          1.40 (0.77--2.56)                                                              1.29 (0.71--2.36)
   Dementia                                                   0.92 (0.62--1.38)          0.89 (0.60--1.34)                                                              0.82 (0.55--1.23)
   Malignancy                                                 1.28 (1.02--1.60)          1.06 (0.85--1.34)                                                              0.94 (0.74--1.20)
   Alcohol abuse                                              2.18 (1.51--3.15)          1.59 (1.08--2.35)                                                              1.55 (1.05--2.28)
   Pulmonary disease                                          1.21 (0.97--1.50)          1.05 (0.84--1.31)                                                              0.95 (0.75--1.19)
   Rheumatic disease                                          1.70 (1.31--2.21)          1.40 (1.07--1.83)                                                              1.30 (0.99--1.71)
   Gastrointestinal disease                                   1.58 (1.33--1.87)          1.10 (0.92--1.33)                                                              1.02 (0.84--1.24)
  Charlson comorbidity index                                                                                                                                            
   0                                                          1.00                       NA                                                                             1.00
   1--3                                                       1.74 (1.46--2.07)          NA                                                                             1.32 (1.06--1.65)
   4--9                                                       3.14 (2.08--4.74)          NA                                                                             1.66 (0.99--2.76)
  Number of drugs                                                                                                                                                       
   1--4                                                       1.00                       NA                                                                             1.00
   5--9                                                       1.82 (1.30--2.55)          NA                                                                             1.56 (1.10--2.20)
   10--14                                                     2.16 (1.53--3.06)          NA                                                                             1.57 (1.06--2.31)
   ≥15                                                        3.14 (2.20--4.50)          NA                                                                             1.88 (1.20--2.93)
  Exposure to interacting drugs                                                                                                                                         
   Drugs with dynamic mechanism of interaction                1.63 (1.38--1.93)          1.43 (1.20--1.71)                                                              1.32 (1.10--1.59)
   Drugs with kinetic mechanism of interaction                1.01 (0.63--1.61)          0.94 (0.59--1.52)                                                              0.90 (0.56--1.44)
   Drugs with unclear mechanism of interaction                1.10 (0.91--1.34)          1.10 (0.90--1.33)                                                              1.05 (1.05--2.28)

**Notes:** History of bleeding during 1 day\<180 days before warfarin initiation treated as a stratifying variable.

Mutually adjusted for all variables except for Charlson comorbidity index and number of drugs;

mutually adjusted for all variables.

**Abbreviations:** CI, confidence interval; HR, hazard ratio; NA, not applicable.
